- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 471/02 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups in which the condensed system contains two hetero rings
Patent holdings for IPC class C07D 471/02
Total number of patents in this class: 508
10-year publication summary
|
22
|
10
|
18
|
31
|
19
|
34
|
35
|
33
|
26
|
14
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Incyte Corporation | 1071 |
17 |
| Merck Sharp & Dohme LLC | 3734 |
12 |
| Merck Patent GmbH | 5728 |
8 |
| Bristol-myers Squibb Company | 4742 |
7 |
| Merck Sharp & Dohme Corp. | 2183 |
7 |
| Boehringer Ingelheim International GmbH | 4493 |
7 |
| Cephalon LLC | 120 |
6 |
| Amgen Inc. | 4427 |
5 |
| Abbvie Inc. | 1836 |
5 |
| Vertex Pharmaceuticals Incorporated | 1582 |
5 |
| Incyte Holdings Corporation | 624 |
5 |
| Medshine Discovery Inc. | 587 |
5 |
| Tolremo Therapeutics AG | 25 |
5 |
| AstraZeneca AB | 2814 |
4 |
| Allergan, Inc. | 2167 |
4 |
| Takeda Pharmaceutical Company Limited | 2712 |
4 |
| Northwestern University | 3543 |
4 |
| Aclaris Therapeutics, Inc. | 88 |
4 |
| BeiGene, Ltd. | 256 |
4 |
| Dana-Farber Cancer Institute, Inc. | 2664 |
4 |
| Other owners | 386 |